# Effect of SHR8058 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction

> **NCT05515471** · PHASE3 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 312 (actual)

## Conditions studied

- Treatment of Dry Eye Disease With Meibomian Gland Dysfunction

## Interventions

- **DRUG:** SHR8058 eye drops
- **DRUG:** saline eye drops.

## Key facts

- **NCT ID:** NCT05515471
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-04
- **Primary completion:** 2021-09-07
- **Final completion:** 2021-09-07
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2022-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05515471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05515471, "Effect of SHR8058 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05515471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*